Almirall, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: $2B

Website

Clinical Trials

A Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris

Phase 3

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Dapsone Gel Vehicle
Drug: Dapsone Gel

First Posted Date: 2013-11-01

Last Posted Date: 2018-10-09

Lead Sponsor: Almirall, S.A.

Target Recruit Count: 2102

Registration Number: NCT01974141

Preference, Satisfaction and Ease of Use of Genuair® (Pressair™) and Breezhaler® (Neohaler™) Inhalers in Patients With COPD

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Device: Genuair®
Device: Breezhaler®

First Posted Date: 2013-08-05

Last Posted Date: 2015-05-29

Lead Sponsor: Almirall, S.A.

Target Recruit Count: 128

Registration Number: NCT01915784

Locations: 🇬🇧
Almirall investigative site 5, Glasgow, United Kingdom
🇪🇸
Almirall investigative site 3, Barcelona, Spain
🇬🇧
Almirall investigative site 6, Newcastle upon Tyne, United Kingdom

and more 3 locations

LAS41008 in Moderate to Severe Chronic Plaque Psoriasis

Phase 3

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: LAS41008
Drug: Placebo
Drug: LASW1835

First Posted Date: 2012-11-15

Last Posted Date: 2015-12-02

Lead Sponsor: Almirall, S.A.

Target Recruit Count: 839

Registration Number: NCT01726933

Locations: 🇳🇱
Investigatives site names will not be disclosed to avoid competitive information. Specify at least one site as follows: Almirall Investigative Site, Various, Netherlands
🇵🇱
Investigatives site names will not be disclosed to avoid competitive information. Specify at least one site as follows:Almirall Investigative Site #, Various, Poland

Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycline in the Treatment of Facial Acne Vulgaris

Phase 2

Completed

Conditions: Acne Vulgaris

Interventions: Drug: 50 mg P005672-HCl
Drug: Placebo
Drug: 100 mg P005672-HCl

First Posted Date: 2012-06-26

Last Posted Date: 2019-02-01

Lead Sponsor: Almirall, S.A.

Target Recruit Count: 285

Registration Number: NCT01628549

Locations: 🇺🇸
Warner Chilcott Investigational Site, Lynchburg, Virginia, United States

Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity

Phase 3

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Sativex®
Drug: Placebo

First Posted Date: 2012-02-24

Last Posted Date: 2014-01-20

Lead Sponsor: Almirall, S.A.

Target Recruit Count: 45

Registration Number: NCT01538225

Locations: 🇮🇹
Institute of Experimental Neurology, Milan, Italy

Efficacy and Tolerability of LAS41004 Formulations in a Non-occlusive Psoriasis Plaque Test

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: LAS41004

First Posted Date: 2011-10-31

Last Posted Date: 2011-10-31

Lead Sponsor: Almirall, S.A.

Target Recruit Count: 22

Registration Number: NCT01462643

Locations: 🇩🇪
Investigational site, Schenefeld, Germany

Study Evaluating Preference, Satisfaction and Ease of Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Diagnosed Patients

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Device: Genuair® (Almirall S.A.)
Device: HandiHaler® (Boehringer Ingelheim's)

First Posted Date: 2011-06-30

Last Posted Date: 2015-06-24

Lead Sponsor: Almirall, S.A.

Target Recruit Count: 130

Registration Number: NCT01385696

Locations: 🇳🇱
Almirall investigative site 2, Zutphen, Netherlands
🇳🇱
Almirall investigative site 1, Enschede, Netherlands
🇩🇪
Almirall investigative site 5, Koblenz, Germany

and more 1 locations

Exploratory Study to Investigate Efficacy of LAS41004 in a Psoriasis Plaque Test

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: LAS41004
Drug: reference

First Posted Date: 2011-05-26

Last Posted Date: 2015-06-08

Lead Sponsor: Almirall, S.A.

Target Recruit Count: 22

Registration Number: NCT01360944

Locations: 🇩🇪
Investigational site, Mahlow, Germany

LAS41005 in Hyperkeratotic Actinic Keratosis

Phase 2

Completed

Conditions: Actinic Keratosis

Interventions: Drug: LAS41005
Procedure: Cryotherapy

First Posted Date: 2011-05-24

Last Posted Date: 2015-05-29

Lead Sponsor: Almirall, S.A.

Target Recruit Count: 67

Registration Number: NCT01358851

Locations: 🇩🇪
Almirall investigative site 4, Soest, Germany
🇩🇪
Almirall investigative site 3, Dülmen, Germany
🇩🇪
Almirall investigative site 1, Leipzig, Germany

and more 1 locations

Clinical Trial to Investigate Efficacy of LAS41004 in Psoriasis

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: Reference

First Posted Date: 2011-01-26

Last Posted Date: 2015-05-29

Lead Sponsor: Almirall, S.A.

Target Recruit Count: 20

Registration Number: NCT01283698

Locations: 🇩🇪
Almirall Investigational Sites#1, Mahlow, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy